This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G71.2 | Special Copayment Reduction: V012 | Coverage period: 5 years |
| B. Synonyms | Myotubular (centronuclear) myopathy, Myotubular Myopathy, X-linked MTM |
| C. Adult onset | Likelihood of first onset in adulthood: low (X-linked severe form) to present (autosomal dominant DNM2 form) — the X-linked form presents severely right after birth; the dominant DNM2 form can present from childhood to adulthood |
| 1. History | → Go to section | First described by Spiro in 1966 |
| 2. Causes | → Go to section | MTM1, DNM2, BIN1, RYR1 genes; dysregulation of membrane lipid metabolism |
| 3. Genetics | → Go to section | X-linked (MTM1), AD (DNM2), AR (BIN1, RYR1, etc.) |
| 4. Epidemiology | → Go to section | X-linked form 1/50,000 male births |
| 5. Pathophysiology | → Go to section | Arrested myotube maturation, impaired membrane remodeling, abnormal organelle positioning |
| 6. Symptoms | → Go to section | X-linked form most severe; DNM2 form mild to moderate |
| 7. Signs | → Go to section | Ptosis, external ophthalmoplegia, facial weakness, respiratory failure |
| 8. Screening | → Go to section | CK normal to elevated, EMG, liver function (MTM1 form) |
| 9. Diagnosis | → Go to section | Muscle biopsy (central nuclei), gene panel |
| 10. Treatment | → Go to section | Supportive care; AT132 gene therapy trial (X-linked MTM1) |
| 11. Prognosis | → Go to section | X-linked form high mortality; dominant form relatively favorable |
| 12. Prevention | → Go to section | Genetic counseling, carrier testing, prenatal genetic diagnosis |
| 13. References | → Go to section | 10 key references |
Myotubular myopathy (MTM) was named in 1966 when Spiro, Shy, and Gonatas first described a congenital myopathy with muscle fibers showing a central nuclear arrangement resembling fetal myotubes. They proposed the name 'myotubular' because the abnormally centrally located nuclei appeared as though maturation had been arrested at the fetal myotube stage of development.
At the same time, Sher et al. described similar pathological findings as 'centronuclear myopathy (CNM)', and the two names have since been used interchangeably. For the X-linked severe form (XLMTM), linkage analysis in the 1990s established that the MTM1 gene is located at Xq28, and in 1996 Laporte et al. first cloned the MTM1 gene, showing that it encodes the myotubularin protein with phosphatase (phosphatidylinositol phosphatase) activity.
In 2002, Bitoun et al. found DNM2 (dynamin-2) mutations in families with autosomal dominant CNM, and in 2007 Nicot et al. identified BIN1 (amphiphysin-2) mutations as a major cause of autosomal recessive CNM. Additional causative genes such as RYR1, TTN, and MTMR14 were subsequently reported. AAV8-mediated MTM1 gene therapy (AT132) for X-linked XLMTM entered clinical trials in 2017 and its early results drew attention, but deaths related to hepatotoxicity occurred in 2021–2022, leading to changes in the conduct of the trial.
CNM/MTM is caused by mutations in genes encoding proteins involved in regulating myotube development, membrane remodeling, and organelle positioning.
| Form | Gene | Mode of inheritance | Severity | Distinctive features |
|---|---|---|---|---|
| X-linked MTM (XLMTM) | MTM1 | X-linked recessive | Most severe | Presents at birth in boys; female carriers may have mild symptoms |
| Autosomal dominant CNM | DNM2 | AD | Mild to moderate | Onset possible from childhood to adulthood; progressive |
| Autosomal recessive CNM | BIN1 | AR | Moderate to severe | Congenital to infancy; facial muscle involvement |
| Autosomal recessive CNM | RYR1 | AR | Variable | CCD or CNM phenotype |
Female MTM1 carriers (heterozygous) are mostly asymptomatic, but with skewed X-inactivation they may show mild weakness or elevated CK. Symptomatic female carriers are also rarely reported. Some DNM2 mutations are de novo, and penetrance is high. DNM2 variants are also associated with Charcot-Marie-Tooth disease (CMT2B2) and intermediate CMT in addition to CNM, so attention to phenotypic diversity is needed.
The prevalence of X-linked XLMTM is estimated at about 1/50,000 male births. Autosomal dominant DNM2-CNM and recessive BIN1-CNM are rarer than XLMTM, with a combined prevalence of about 1–2/100,000. Taken together, CNM is estimated to account for about 15–20% of congenital myopathies.
XLMTM presents severely only in boys, and symptoms rarely appear in girls. DNM2-CNM occurs without sex difference, with a variable age of onset spanning childhood to adulthood. In Korea it is covered by the rare disease Special Copayment Reduction, and the diagnosis rate is rising with improved access to genetic testing.
The core pathophysiology of CNM is arrested muscle fiber maturation and impaired membrane remodeling. In normal muscle development, multinucleated myotubes form during fetal life, after which the nuclei migrate to the periphery and myofibrils fill the center as they differentiate into mature muscle fibers. In CNM this maturation process is interrupted, so the nuclei remain in the center.
Myotubularin (MTM1) dephosphorylates phosphatidylinositol-3-phosphate (PI3P) and PI(3,5)P₂ to regulate the endosome–lysosome pathway and maintains the structure and function of the T-tubules (transverse tubules) and sarcoplasmic reticulum (SR). MTM1 deficiency leads to PI3P accumulation, resulting in impaired endosome maturation, T-tubule dysgenesis, abnormal SR–T-tubule coupling, and impaired calcium release for muscle contraction.
Dynamin-2 (DNM2) is a GTPase involved in various cellular processes including clathrin-mediated endocytosis, Golgi maintenance, and actin–myosin cytoskeletal remodeling. DNM2 mutations cause abnormal myotube maturation through impaired intracellular membrane trafficking. BIN1 senses membrane curvature through its BAR domain and participates directly in T-tubule formation. BIN1 deficiency causes T-tubule dysgenesis and abnormal calcium signaling.
Interestingly, preclinical studies have shown that MTM1 overexpression can prevent and rescue the phenotype in DNM2- and BIN1-related CNM mouse models, suggesting that the MTM1–DNM2–BIN1 pathway is linked as a common pathogenic network.
⚠ Hepatotoxicity caution: In XLMTM patients (MTM1 variants), watch for liver abnormality findings. Deaths from severe hepatotoxicity were reported in the trial of high-dose AAV vector-mediated gene therapy (AT132). Because hepatic fibrosis can also occur as a congenital associated abnormality in MTM1 patients, regular monitoring of liver function is needed.
| Test | Findings and significance |
|---|---|
| Serum CK | Normal to mildly elevated. Normal range common in XLMTM. |
| EMG | Myopathic findings; spontaneous potentials (fasciculations, positive sharp waves) observed in some. |
| Liver function tests (LFT) | Monitoring for hepatic fibrosis in patients with MTM1 variants. Includes AST/ALT, bilirubin, GGT. |
| Muscle MRI | Characteristic pattern reflecting T-tubule dysgenesis; central signal abnormality (central shading) observed in some. |
| Pulmonary function tests | FVC, MIP, MEP; nocturnal SpO₂ monitoring. |
| Ophthalmologic examination | Evaluation of ptosis and extraocular muscle abnormalities. |
On light microscopy, nuclei are concentrated in the center of muscle fibers (centrally located nuclei). Perinuclear halo pattern that is negative for or overexpresses oxidative enzymes (NADH-TR, SDH). Type 1 fiber predominance and atrophy. T-tubule dysgenesis observed on electron microscopy.
The location of central nuclei differs from CCD (core findings), and differentiation from multiminicore disease and congenital fiber-type disproportion is also needed. Immunohistochemical staining confirms loss of myotubularin (MTM1) protein (supports XLMTM diagnosis).
XLMTM has traditionally had a very poor prognosis, and neonatal death was common without mechanical ventilation. With long-term mechanical ventilation support, a considerable number of survivors can reach adulthood, but severe respiratory and motor impairment persists. Some reports give a life expectancy of 10–20 years, but cases of survival into adulthood with active supportive care are increasing.
Autosomal dominant DNM2-CNM shows slow progression and a relatively favorable prognosis, and many patients lead independent lives with appropriate respiratory support and rehabilitation. BIN1-CNM has a prognosis between moderate and severe, with the rate of progression depending on the variant type. In patients with MTM1 variants and associated liver abnormalities, hepatic complications can be an additional factor worsening the prognosis.